Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | ERBB3 G284R |
| Therapy | Neratinib + Palbociclib |
| Indication/Tumor Type | Her2-receptor positive breast cancer |
| Response Type | predicted - sensitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| ERBB3 G284R | Her2-receptor positive breast cancer | predicted - sensitive | Neratinib + Palbociclib | Case Reports/Case Series | Actionable | In a Phase I trial, treatment with the combination of Nerlynx (neratinib) and Ibrance (palbociclib) resulted in an objective response rate of 16.7% (5/30, all partial responses) and clinical benefit rate of 26.7% in patients with advanced solid tumors harboring HER alterations, including a partial response in a patient with ESR1-positive, ERBB2 (HER2)-positive breast cancer harboring ERBB3 G284R (PMID: 41223631; NCT03065387). | 41223631 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (41223631) | Phase I trial of neratinib plus palbociclib in advanced cancers with HER family alterations. | Full reference... |